Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/36047
DC FieldValueLanguage
dc.contributor.authorRodríguez, Marioen_US
dc.contributor.authorMárquez, Saioaen_US
dc.contributor.authorDe La Rosa Medina, Vladimiren_US
dc.contributor.authorAlonso, Saraen_US
dc.contributor.authorCastrillo Viguera, Antonioen_US
dc.contributor.authorSánchez Crespo, Marianoen_US
dc.contributor.authorFernández, Nievesen_US
dc.date.accessioned2018-05-11T12:25:30Z-
dc.date.available2018-05-11T12:25:30Z-
dc.date.issued2017en_US
dc.identifier.issn0019-2805en_US
dc.identifier.urihttp://hdl.handle.net/10553/36047-
dc.description.abstractCyclic AMP regulatory element binding protein and signal transducer and activator of transcription 3 (STAT3) may control inflammation by several mechanisms, one of the best characterized is the induction of the expression of the anti-inflammatory cytokine interleukin-10 (IL-10). STAT3 also down-regulates the production of pro-inflammatory cytokines induced by immunoreceptor tyrosine-based activation motif (ITAM)-coupled receptors, a mechanism termed cross-inhibition. Because signalling via ITAM-dependent mechanisms is a hallmark of fungal pattern receptors, STAT3 activation might be involved in the cross-inhibition associated with invasive fungal infections. The fungal surrogate zymosan produced the phosphorylation of Y705-STAT3 and the expression of Ifnb1 and Socs3, but did not induce the interferon (IFN)-signature cytokines Cxcl9 and Cxcl10 in bone marrow-derived dendritic cells. Unlike lipopolysaccharide (LPS), zymosan induced IL-10 and phosphorylated Y705-STAT3 to a similar extent in Irf3 and Ifnar1 knockout and wild-type mice. Human dendritic cells showed similar results, although the induction of IFNB1 was less prominent. These results indicate that LPS and zymosan activate STAT3 through different routes. Whereas type I IFN is the main effector of LPS effect, the mechanism involved in Y705-STAT3 phosphorylation by zymosan is more complex, cannot be associated with type I IFN, IL-6 or granulocyte-macrophage colony-stimulating factor, and seems dependent on several factors given that it was partially inhibited by the platelet-activating factor antagonist WEB2086 and high concentrations of COX inhibitors, p38 mitogen-activate protein kinase inhibitors, and blockade of tumour necrosis factor-alpha function. Altogether, these results indicate that fungal pattern receptors share with other ITAM-coupled receptors the capacity to produce cross-inhibition through a mechanism involving STAT3 and induction of SOCS3 and IL-10, but that cannot be explained through type I IFN signalling.en_US
dc.languageengen_US
dc.relation.ispartofImmunologyen_US
dc.sourceImmunology [ISSN 0019-2805], v. 150 (2), p. 184-198en_US
dc.subject2412 Inmunologíaen_US
dc.subject32 Ciencias médicasen_US
dc.subject.otherCytokinesen_US
dc.subject.otherDendritic cellsen_US
dc.subject.otherFungal infectionen_US
dc.subject.otherInflammationen_US
dc.titleFungal pattern receptors down-regulate the inflammatory response by a cross-inhibitory mechanism independent of interleukin-10 productionen_US
dc.typeinfo:eu-repo/semantics/Articlees
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticlees
dc.identifier.doi10.1111/imm.12678
dc.identifier.scopus85002388948-
dc.identifier.isi000394790400007-
dc.contributor.authorscopusid56411145300
dc.contributor.authorscopusid57002865900
dc.contributor.authorscopusid55926663500
dc.contributor.authorscopusid7102615617
dc.contributor.authorscopusid55445301000
dc.contributor.authorscopusid35432052000
dc.contributor.authorscopusid7102523522
dc.identifier.eissn1365-2567-
dc.description.lastpage198-
dc.identifier.issue2-
dc.description.firstpage184-
dc.relation.volume150-
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.contributor.daisngid5287488
dc.contributor.daisngid10012329
dc.contributor.daisngid6668944
dc.contributor.daisngid9454061
dc.contributor.daisngid225640
dc.contributor.daisngid251681
dc.contributor.daisngid1807356
dc.contributor.wosstandardWOS:Rodriguez, M
dc.contributor.wosstandardWOS:Marquez, S
dc.contributor.wosstandardWOS:de la Rosa, JV
dc.contributor.wosstandardWOS:Alonso, S
dc.contributor.wosstandardWOS:Castrillo, A
dc.contributor.wosstandardWOS:Crespo, MS
dc.contributor.wosstandardWOS:Fernandez, N
dc.date.coverdateFebrero 2017
dc.identifier.ulpgces
dc.description.sjr1,69
dc.description.jcr3,358
dc.description.sjrqQ1
dc.description.jcrqQ2
dc.description.scieSCIE
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.deptGIR IUIBS: Farmacología Molecular y Traslacional-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Bioquímica y Biología Molecular, Fisiología, Genética e Inmunología-
crisitem.author.deptGIR IUIBS: Farmacología Molecular y Traslacional-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.orcid0000-0003-1443-7548-
crisitem.author.orcid0000-0002-2057-2159-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameDe La Rosa Medina, Juan Vladimir-
crisitem.author.fullNameCastrillo Viguera, Antonio Jesús-
Appears in Collections:Artículos
Show simple item record

SCOPUSTM   
Citations

10
checked on Dec 1, 2024

WEB OF SCIENCETM
Citations

10
checked on Nov 24, 2024

Page view(s)

49
checked on Jul 27, 2024

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.